Skip to content

A multi-center study examining the risk factors and controllable methods for patients with premature ejaculation, focusing on both psychological and physiological perspectives

A multi-center study examining the risk factors and controllable methods for patients with premature ejaculation, focusing on both psychological and physiological perspectives

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600117830
Enrollment
Unknown
Registered
2026-01-29
Start date
2022-03-20
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Premature ejaculation

Interventions

Observation group:None

Sponsors

Zhongnan Hospital of Wuhan University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Select outpatient patients from urology and urology departments who have been clinically diagnosed with premature ejaculation based on their chief complaint, physical examination, and auxiliary examinations, and voluntarily participate and sign an informed consent form 1.The enrolled patients are premature ejaculation patients 2.The patient is aged 18-50 years old and generally in good physical condition 3.The patient has a fixed sexual partner, has had regular sexual activity for more than six months, and has had six or more sexual activities in the past month; Ensure 1-2 sexual activities per week during the study period. 4.Diagnosis of primary premature ejaculation 5.Diagnosis of peripheral premature ejaculation: quantitative sensation threshold measurement or penile vibration threshold measurement

Exclusion criteria

Exclusion criteria: 1.Exclude those who have taken serotonergic active drugs (such as ketamine), SSRIs, TCA preparations, PDE5i, and those who must take the above drugs during the trial period within the 4 weeks prior to screening; 2.Exclude individuals with comorbidities of mental illness, cardiovascular and cerebrovascular diseases, liver and kidney dysfunction, and alcohol dependence; 3.Exclude individuals with erectile dysfunction (assessed using the IIEF-5 scoring system for erectile function); 4.Individuals known to be allergic to the study drug and its excipient components

Design outcomes

Primary

MeasureTime frame
Intravaginal ejaculation latency, IELT;

Secondary

MeasureTime frame
Diagnostic tools for premature ejaculation, PEDT;Penile erectile function score, IIEF-5;

Countries

China

Contacts

Public ContactSu Xinjun

Zhongnan Hospital of Wuhan University

1919519046@qq.com+86 159 0717 6726

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026